Vertex Pharmaceuticals IncorporatedVRTX

Is VRTX cheap right now? Every multiple below is scored against its own 10-year range, not a sector average.

$540.00+10.31 (+1.95%)24:00 UTC
NASDAQHealthcare

Company snapshot

Market Cap
$138B
Large-cap
+597%
2016 — today
10-Year Price
+568%
2016 — today
52-Week Range
$409.47$557.96
Current $540.00· 88%

Vertex Pharmaceuticals focuses on discovering and marketing innovative treatments, primarily for cystic fibrosis (CF). Its portfolio includes KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI, and TRIKAFTA, which target specific CFTR gene mutations. Beyond CF, the pipeline includes VX-880 for Type 1 Diabetes, VX-548 for pain, and CTX001 for sickle cell disease and beta-thalassemia. Vertex distributes globally through specialty networks and maintains strategic R&D collaborations with partners like CRISPR Therapeutics and Moderna.

Featured in rankings

Rankings recomputed after each US market close — see where VRTX stands against peers.

Similar companies

Healthcare companies of comparable size to VRTX
CompanyP/EDiv yield
BMYBristol-Myers Squibb Company13.64.1%
MDTMedtronic plc24.63.0%
ISRGIntuitive Surgical, Inc.53.9—
SYKStryker Corporation33.21.1%
MCKMcKesson Corporation26.20.4%
CVSCVS Health Corporation23.92.9%
DHRDanaher Corporation38.80.6%
PFEPfizer Inc.39.65.7%

Healthcare companies of comparable size — each one shown against its own 10-year range, not a sector average. Browse all stocks we cover.

Valuation in context

P/E ratio
31.4
Above average
Pricier than usual over the last 10 years
Sector median 25.2above sector
P/B ratio
6.8
Around average
Around the 10-year average
Sector median 2.2above sector
EV / EBITDA
24.3
Around average
Around the 10-year average
Sector median 15.4above sector
PEG ratio
2.0
Above average
Pricier than usual over the last 10 years
Sector median 1.8above sector
FCF Yield
2.8%
Below average
Below the 10-year average
Sector median -12.6%above sector
Free · No credit card needed

Get alerted when VRTX is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.